Background. Delayed graft function (DGF) is an established complication after donation after cardiac death (DCD) kidney transplants, but the impact of DGF on graft outcomes is uncertain. To minimize donor variability and bias, a paired donor kidney analysis was undertaken where 1 kidney developed DGF and the other did not develop DGF using data from the Australia and New Zealand Dialysis and Transplant Registry. Methods. Using paired DCD kidney data from the Australia and New Zealand Dialysis and Transplant Registry, we examined the association between DGF, graft and patient outcomes between 1994 and 2012 using adjusted Cox regression models. Results. Of the 74 pairs of DCD kidneys followed for a median of 1.9 years (408 person-years), a greater proportion of recipients with DGF had experienced overall graft loss and death-censored graft loss at 3 years compared with those without DGF (14% vs 4%, P = 0.04 and 11% vs 0%, P < 0.01, respectively). Compared with recipients without DGF, the adjusted hazard ratio for overall graft loss at 3 years for recipients with DGF was 4.31 (95% confidence interval [95% CI], 1.13-16.44). The adjusted hazard ratio for acute rejection and all-cause mortality at 3 years in recipients who have experienced DGF were 0.98 (95% CI, 0.96-1.01) and 1.70 (95% CI, 0.36-7.93), respectively, compared with recipients without DGF. Conclusions. Recipients of DCD kidneys with DGF experienced a higher incidence of overall and death-censored graft loss compared with those without DGF. Strategies aim to reduce the risk of DGF could potentially improve graft survival in DCD kidney transplants.
D
onation after cardiac death (DCD) is an important source of donor kidneys worldwide. In Australia, the number of DCD kidney transplants has increased by at least 4 times between 2007 and 2013, with similar trend being observed in other countries. 1 The initial concerns that DCD kidneys are associated with poorer graft outcomes compared with donation after brain death (DBD) kidney transplants have largely been allayed, with large registry analyses from the United Kingdom and United States showing similar short-term and medium-term graft outcomes in recipients of DCD and DBD kidneys. [2] [3] [4] Although the influence of the mechanisms of donor death on longer-term graft outcomes is unclear, there is now evidence showing the incidence of other short-term adverse effects such as delayed graft function (DGF) is substantial and is increasing, owing to the use of more marginal donor kidneys and DCD kidneys for transplantation.
Delayed graft function is an established risk factor for adverse graft outcomes in DBD kidney transplants, with a recent meta-analysis showing that the presence of DGF is associated with a 38% and 41% relative increase in the risk of acute rejection and graft loss at 3.2 years follow-up, respectively. 5 By contrast, the association between DGF and graft outcomes in DCD kidney transplants is less clear, with several studies suggesting similar graft outcomes between recipients of DCD kidneys who had experienced DGF and no DGF. 6, 7 Although DCD kidneys are more susceptible to the deleterious effects of cold ischemic injury compared with DBD kidneys, it has been shown that brain death induces a greater upregulation of inflammatory gene expression profile in the DBD kidneys compared with DCD kidneys, which may to some extent explain why DGF in DCD kidneys may not have the same deleterious effects on graft survival as DBD kidneys. 8 Nevertheless, the impact of DGF on graft outcomes remains uncertain because multiple donor and recipient characteristics often modify graft outcomes despite being adjusted for in statistical models. Taking into consideration that within pair donor kidney analysis may be a more accurate and reliable method of assessing the association between the study factor of interest and graft outcomes, the aim of this study was to examine the association between DGF and graft and patient outcomes using paired kidney data.
MATERIALS AND METHODS

Study Population
Of the 201 paired primary DCD kidney transplant recipients identified between 1994 and 2012 using Australia and New Zealand Dialysis and Transplant (ANZDATA) registry, 74 pairs were included in this study because of differences in the presence of DGF (ie only 1 of the 2 recipients from the same DCD donor experienced DGF, defined as requiring dialysis after transplantation). We excluded recipients of multiple organ grafts and DCD kidney transplants where both recipients from the same DCD donor experienced either no DGF or DGF. ANZDATA registry does not collect the reason for DGF and therefore, we were unable to differentiate between DGF (and therefore requiring dialysis) secondary to hyperkalemia or other reasons.
Data Collection
Baseline data included recipient characteristics of age, sex, cause of end-stage kidney disease, race, body mass index (BMI) (in kg/m 2 ), waiting time (in years), presence of comorbidities (diabetes, coronary artery disease) and smoking history; and transplant-related characteristics included the use of induction antibody therapy, HLA mismatches, percentage peak panel-reactive antibody, total ischemic time, and type of initial immunosuppressive agents (categorized as calcineurin inhibitor, antimetabolite and prednisolone).
Clinical Outcomes
The primary clinical outcomes of this study were overall graft loss, death-censored graft loss (DCGL), acute rejection in the first 6 months after transplant, graft function (estimated glomerular filtration rate [eGFR]), all-cause mortality and death with functioning graft. Graft loss, eGFR, and death were examined at 1 and 3 years posttransplant.
Statistical Analyses
Comparisons of the baseline characteristics between recipients who had experienced no DGF or DGF were made by χ 2 test, Mann-Whitney U test and analysis of variance for categorical and continuous variables, respectively, where appropriate. Overall graft loss, DCGL, acute rejection at 6 months, all-cause mortality, and death with functioning graft were examined using the adjusted Cox proportional hazard regression analysis. In addition, random effects (shared frailty) Cox proportional hazard regression models, accounting for the potential intracluster correlation within transplant states and country were undertaken for analysis involving graft loss. Linear regression was used to examine the association between DGF and eGFR at 1 and 3 years.
Graft loss censored for death was coded as 0 mL/min per 1.73m 2 . The proportional hazard assumptions of all Cox regression models were checked graphically by plotting the Schoenfield residuals, with no evidence of departures from proportional hazards for overall graft loss, DCGL, all-cause mortality, and death with functioning graft. The covariates included in the Cox and linear regression models were recipient and transplant-related characteristics outlined above. Results were expressed as hazard ratio (HR) or mean differences with 95% confidence interval (95% CI). Potential effect modification was tested between the study factor and other covariates using 2-way interaction terms in the adjusted models. Only covariates which were associated with outcomes with P values less than 0.10 in the unadjusted analyses were included in the multivariable-adjusted analyses. Recipient age was included in all models given its "biological" relationship with outcomes. All analyses were undertaken using SPSS V10 statistical software program (SPSS Inc., North Sydney, Australia) and SAS statistical software 9.4.
RESULTS
Study Population
The mean (SD) age of the 74 donors was 45.2 (16.3) years. Fifty (67.6%) donors were men, 13 (17.8%) had a history of hypertension and 25 (33.8%) whose death were attributed to cerebrovascular accident. Table 1 Recipients who had experienced DGF had a higher mean BMI compared to those without DGF (27.7 vs 24.9 kg/m 2 , P < 0.01) but other recipient characteristics, total ischemic time, baseline immunological status, and initial immunosuppression were similar between groups. Median (IQR) duration of dialysis in recipients who had experienced DGF was 9 (5-14) days.
Proportion of recipients who had experienced rejection or had died were similar between those with and without DGF. A greater proportion of recipients with DGF had experienced DCGL compared with those without DGF, with the majority of the DCGL occurring within the first 3 years posttransplant (Table 1) .
Delayed Graft Function, Overall, and DCGL
The unadjusted cumulative overall graft survivals at 1 and 3 years for recipients without DGF were 95% and 95% respectively; and were 90% and 83%, respectively, for recipients with DGF (log-rank P = 0.04). Compared with recipients without DGF, the adjusted HR for 1-year overall graft loss for recipients with DGF was 2.75 (95% CI, 0.68-11.01) and was 4.31 (95% CI, 1.13-16.44) for 3-year overall graft loss, adjusted for HLA mismatches, waiting time, recipient age, and smoking status (Figure 1 ). The adjusted HR in the random effects models for 1-and 3-year overall graft loss were 2.39 (95% CI, 0.62-9.28; P = 0.200) and 3.40 (95% CI, 0.94-12.4; P = 0.060) respectively. Adjusted Kaplan-Meier curves for overall graft survivals according to DGF status are shown in Figure 2A .
Causes of graft loss at 3 years by DGF status are shown in Table 1 . Median (IQR) time to overall graft loss was similar between recipients with and without DGF (3.8 [1.9-12.6] months vs 2.0 [-] months respectively, P = 0.47).
The unadjusted cumulative death-censored graft survivals at 1 and 3 years for recipients without DGF were 100% and 100%, respectively and were 91% and 86%, respectively, for recipients with DGF (log-rank P value = 0.03). Recipients without DGF did not experienced DCGL in the first 3 years after transplantation. Adjusted Kaplan-Meier curves for death-censored graft survivals according to DGF status are shown in Figure 2B .R Delayed Graft Function, Acute Rejection, and Graft Function There were no associations between DGF and acute rejection at 6 months in the unadjusted and adjusted models. The adjusted HR for acute rejection for recipients with DGF was 0.98 (95% CI, 0.96-1.01), adjusted for recipient age, initial immunosuppression, and panel-reactive antibody (Figure 1 ).
The mean (SD) eGFR at 1 and 3 years for recipients with and without DGF are shown in Table 1 
Delayed Graft Function and Mortality
The cumulative patient survivals at 1 and 3 years for recipients with and without DGF were 96% and 96%, respectively. Compared with recipients without DGF, the adjusted HRs for all-cause mortality and death with functioning graft at 1 year for recipients with DGF were 1.26 (95% CI, 0.25-6.49) and 0.41 (95% CI, 0.04-4.21), respectively, and at 3 years were 1.70 (95% CI, 0.36-7.93) and 0.80 (95% CI, 0.12-5.18), respectively, adjusted for recipient age, diabetes, smoking status, and waiting time (Figure 1 ).
DISCUSSION
In our study involving 74 paired DCD kidney transplants with a median follow-up time of 1.9 years, we have shown that DGF is associated with a higher incidence of overall graft loss and DCGL at 3 years. At 3 years after transplantation, 14% of kidney transplant recipients who had experienced DGF experienced DCGL, compared with no patients who did not experience DGF. Delayed graft function is a frequent complication of DCD kidney transplants, with reported incidence of almost 50% compared with 20% for DBD kidney transplants, attributed to the greater susceptibility of DCD kidneys to the deleterious effects of cold ischemia. 9 Delayed graft function occurs at a result of ischemia-reperfusion injury. In the ensuing ischaemic injury after organ procurement, there is osmotic injury to cells in addition to an accumulation of reactive oxygen species 10, 11 ; the damage of which can be reduced with appropriate preservation fluids, optimal storage conditions, and adequate intraoperative and postoperative fluid balance.
12-14 After reperfusion, the combination of vasoconstriction, activation, and recruitment of innate and adaptive immune cells contributes to sustained epithelial cell damage and inflammatory response, manifesting clinically as DGF. 15, 16 In a prospective longitudinal study of 318 kidney transplant recipients, kidneys that were complicated by DGF showed significantly higher degrees of tubulointerstitial inflammation (ie, higher Banff t and i scores) and higher Banff cumulative chronicity scores in protocol biopsy at 3 months compared with kidneys without DGF, suggesting a potential role of inflammation in determining the longer-term graft outcomes in recipients with DGF. 17 With the greater utilization of DCD donors as a source of donor kidneys worldwide, it is therefore crucial to understand whether there is a differential association between DGF and graft survival in DCD compared with DBD kidney transplants.
The impact of DGF on overall graft function and graft loss is uncertain from the published literature. A recent systematic review of 33 randomized controlled trials, cohort, and case control studies involving 151 194 kidney transplant recipients evaluating the impact of DGF and graft outcomes reported there was substantial heterogeneity in the current literature, limited by varying duration of follow-up period, definition of DGF and year of publication. In that study, the pooled relative risk for graft loss in recipients with DGF was 1.41 (95% CI, 1.27-1.56, df = 20, P < 0.01, I 2 = 52%) compared to those without DGF, with little difference in the point estimates if restricted to studies that had defined DGF as requiring dialysis (pooled relative risk, 1.42; 95% CI, 1.24-1.63; df = 12; P < 0.01; I 2 = 61%). 5 This metaanalysis included 2 DCD cohort studies, which showed that in contrast to DBD kidney transplants, there was no association between DGF and graft loss. 18, 19 Similar findings of a lack of association between DGF and graft survival in DCD kidneys have been corroborated by other single centre retrospective cohort studies. 6, 7 Our study findings suggested a higher incidence of overall graft loss and DCGL in DCD recipients who have experienced DGF, the causal relationship between DGF and overall graft loss and DCGL is not clear. There was no association between DGF and acute rejection suggesting that the greater risk of DCGL in recipients who had experienced DGF was not mediated by acute clinical rejection. In addition, there was no distinct pattern of graft loss in those with DGF, with graft loss attributed to acute rejection being reported for 8% of overall graft loss. There have been a few studies that have used paired kidneys for analysis, which minimizes donor and hidden selection biases and may offer a more accurate assessment of the association between the study factor and outcome of interest.
There are several limitations in our study. Even though a paired kidney approach was used, selection bias may still exist because there may be systematic differences in the management of kidney transplant recipients between transplanting centres and clinicians. There may be unmeasured residual confounders such as the surgical approach/ complications (eg, duration of anastomotic time, complexities of recipient surgery) and intensity of immunosuppression (ie, therapeutic drug levels), which are not collected by ANZDATA registry but may have modified the association between DGF and graft loss. 20 In view of the lack of detailed descriptor within the ANZDATA registry, misclassification bias of the outcomes could potentially occur but the bias is likely to be random and nondifferential between the exposed and unexposed groups. The limited sample size and short follow-up period may lead to erroneous inference and therefore we are unable to generate reliable estimates with certainty. Despite these limitations, our study is the first paired kidney analysis that has evaluated the influence of DGF and graft and patient outcomes in DCD kidney transplants.
With the improved understanding of the complex mechanisms that cause DGF in DCD kidney transplants, therapeutic targets that modify these pathways could potentially reduce the development of DGF. Our study provides the point estimates that may be used to design a clinical trial using agents capable of reducing DGF and therefore reducing the risk of graft loss in DCD transplants.
CONCLUSIONS
Delayed graft function remains a vexing complication of DCD kidney transplants. In contrast to other studies, our paired kidney analysis has challenged the previously held belief that DGF has no deleterious effect on graft outcome by showing that 3-year death-censored graft survival for DCD recipients was 14% lower compared with those who did not experience DGF. Even though small numbers of DCD recipients were included in this study with short followup period, this is an important finding given the increased utilization of DCD kidneys worldwide. Strategies aim to reduce the risk of DGF could potentially improve graft survival in DCD kidney transplants.
